Suda Pharmaceuticals share price soars 200% on TGA approval

The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Suda Pharmaceuticals Ltd (ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company's announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia. 

In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, according to the National Institutes of Health, as reported by Sleep Foundation, an estimated 30% of the general population complains of sleep disruption and 10% have associated symptoms during the day.

TGA approval

The approval follows an announcement from Suda Pharmaceuticals on 12 May 2020 outlining its decision to register a supplemental active pharmaceutical ingredient (API) supplier and manufacturer which required an amendment to an existing TGA submission. Therefore, today's decision will benefit the company by reducing the costs of raw material and its finished product to create increased value. 

According to the market release today, the TGA approval was achieved ahead of a projected Q4 2020 deadline. The decision enables Suda's Zolpimist product to be sold in Australia, allows more competitive pricing and supports further submissions across more locations. 

Suda Pharmaceuticals CEO and Managing Director, Dr Michael Baker, commented:

"The TGA submission was a combined effort by Suda's technical team as well as our regulatory consultant, Pharma to Market. Obtaining the approval indicates the calibre of our staff and is also a key benefit to our partners for ZolpiMist. We are delighted by the outcome and look forward to seeing the commencement of commercial sales in the foreseeable future".

Other recent announcements

Earlier this month, Suda Pharmaceuticals raised $3.56 million in an entitlement offer. The purpose of the funds was to assist with the development of the company's anagrelide technology, which is used in the treatment of cancer, and its OroMist platform. The funds are also earmarked to be used for potential acquisition of new assets and general working capital.

About the Suda Pharmaceuticals share price

According to its website, Suda Pharmaceuticals is a leader in reformulating and delivering medications through the use of oral sprays. It argues patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream. This compares to up to 95% absorption through a simple spray into the mouth.

The company's product, ZolpiMist, is also FDA (Food and Drug Administration) approved in the United States. 

At time of writing the Suda Pharmaceuticals share price is trading at 8.3 cents.

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A fun depiction of summer Santa Claus -- wearing red swimming trunks and Hawaiian shirt -- sitting in a deck chair on his laptop at the beach.
Opinions

2 ASX stocks on my naughty list this Christmas

Nothing but coal in the stockings of these disappointing companies.

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Record Highs

The multi-billion-dollar ASX tech share hitting new highs on broker bullishness

This ASX tech share darling is up 216% in the year to date and just reset its record price.

Read more »

Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.
Resources Shares

Fortescue shares are galloping again as Twiggy stays confident in China's horsepower

It's business as usual for the miner despite Trump's promised 60% tariffs on Chinese imports.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

How these 3 ASX 200 stocks led the charge higher this week

The three top ASX 200 stocks are up 14% to 34% this week.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

These shares are ending the week on a high. But why? Let's find out.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Arcadium Lithium, Block, Jumbo, and Mineral Resources shares

These shares are ending the week in the red. Why are investors selling them?

Read more »

Rising green bar graph with an arrow and a world map, symbolising a rising share price.
Share Market News

ASX 200 racing higher on Friday as US Fed slashes interest rates again

The ASX 200 is enjoying a strong run amid lower US interest rates.

Read more »